Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL)

Auro Del Giglio, Susan O'brien, Richard J. Ford, John Manning, Hideyuki Saya, Michael Keating, Dennis Johnston, Dalton Fisher Chamone, Albert B. Deisseroth

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)


Chronic Lymphocytic Leukemia (CLL) is usually an indolent disorder which in some patients assumes an aggressive clinical course. In order to assess at presentation the prognosis of a given patient, several staging systems and prognostic variables have been proposed including the expression of the Proliferating Cell Nuclear Antigen (PCNA). PCNA is a 36 kd nuclear protein, the regulation of which is cell cycle-dependent. In CLL, PCNA levels correlate with cell proliferation, clinical stage and the lymphocyte doubling time (LDT). Furthermore, preliminary data suggests that PCNA expression may also predict response to Fludarabine-based chemotherapy. Since PCNA is a cofactor for Delta DNA polymerase, PCNA overexpression in CLL may also reflect the intrinsic DNA repair activity of the leukemic cells and thus their resistance to chemotherapy. Further studies aiming at modulation of PCNA expression in CLL cells may clarify this issue and may offer a future new therapeutic strategy with which to treat this disorder.

Original languageEnglish
Pages (from-to)265-271
Number of pages7
JournalLeukemia and Lymphoma
Issue number4-5
Publication statusPublished - 1993
Externally publishedYes


  • CLL
  • Chronic lymphocytic leukemia
  • PCNA
  • Proliferating cell nuclear antigen

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL)'. Together they form a unique fingerprint.

Cite this